AoFrio updates guidance
A: 21 Arrenway Drive, Rosedale, Auckland 0632, New
Zealand PO Box: 302-533 North Harbour, Auckland 0751,
New Zealand
P: + 64 9 477 4500 E: info@aofrio.com
® is a registered Trademark of AoFrio Ltd.
23 November 2022
Market Announcement
For immediate release
AoFrio updates guidance
On 31 October AoFrio announced that the Company expected annual EBITDA* to fall towards the lower end
of a $3.5 – $4.5 million range, due to some customers pushing orders out of Q4-2022 into Q1-2023.
Revenue was expected to be around $83 million for the year.
Whilst Q4 trading volumes are tracking significantly above what was recorded earlier this year (see table
below), we continue to see customers delaying deliveries until next year due to inventory management.
NZ$000s 2022 2021
Q1 18.4 14.6
Q2 13.5 15.9
Q3 18.1 15.3
Q4 forecast 29.5 18.3
Full Year forecast 79.5 64.2
We now expect revenue to fall between $79 – $80 million, which represents a 23 – 25% increase compared
to the 2021 year. This revenue result is expected to deliver an EBITDA result in the range $2.5 to $3.0
million.
AoFrio remains on track to becoming a NZ$100 million revenue company in 2023, which indicates revenue
growth in the 20-30% range during FY23.
The Company has significant opportunities with its new product range and new customer targets and
expects strong demand in these areas. However, the Company remains cautious about its base demand,
given elevated global macroeconomic risks from rising interest rates that could slow global growth and
impact future revenue.
*EBITDA (i.e., Earnings before interest, taxation, depreciation, amortisation, and impairment) is a non-GAAP
earnings figure that equity analysts tend to focus on for comparable company performance analysis. AoFrio
considers it a valuable financial indicator because it avoids the distortions caused by differences in
amortisation and impairment policies. Contact
Greg Balla Howard Milliner
Chief Executive Officer Chief Financial Officer
Phone + 64 21 938 601 +64 27 587 0455
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- AFT — AFT Pharmaceuticals Limited: 2023 New Year letter to investors2023-01-08
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 9 January 2023 2023 New Year letter to investors AFT Pharmaceuticals (NZX: A…”
- AFT — AFT Pharmaceuticals Limited: AFT extends growth investment as sales surge2022-11-23
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 24 NOVEMBER 2022 FINANCIAL RESULTS FOR THE SIX MONTHS TO 30…”
- AFT — AFT Pharmaceuticals Limited: 221124 Interim results FY23H1 App 2 amended2022-11-23
“Results for announcement to the market AFT Pharmaceuticals Limited Reporting Period 6 months to September 30 2022 Previous Reporting Period 6 months to September 30 2021 Currency NZ$ Amount (000s) Percentage change Revenue from continuing operations $65,750 Up 18%…”